Upcoming catalysts for the first quarter of 2024 include approval decisions by the US FDA on resmetirom for nonalcoholic steatohepatitis (NASH) with liver fibrosis, atidarsagene autotemcel for metachromatic leukodystrophy and marnetegragene autotemcel for leukocyte adhesion deficiency type 1 (LAD1).

The author declares no competing interests.